Imiquimod is a clinically approved, topical treatment for SCC/BCC and can induce type 1 IFN signaling through interaction with TLR7 leading to the downstream recruitment of CXCR3+ T cells (137). Here, CXCR3 is linked to skin basal cell carcinoma.